Spotlight On... Gilead's hep C meds keep churning, but execs see need for deals as U.S. sales slow; Sun undercuts Novartis' Gleevec price by 30%; AZ's Tagrisso nabs quick EU approval; and more...

Gilead Sciences ($GILD) and its hep C juggernaut kept rolling in Q4, churning out street-beating sales of $4.9 billion. But it took strong growth overseas to overcome an expected falloff for Sovaldi and Harvoni in the U.S. While Gilead execs say there's lots of growth left in the hep C market, they acknowledged Tuesday that the company needs to be looking for M&A opportunities in areas such as oncology. Report

> Sun Pharmaceuticals discounted its new copycat version of Novartis' ($NVS) Gleevec by 30% to the brand, hoping to make big inroads in the market for leukemia treatments. Report

> AstraZeneca's ($AZN) Tagrisso (osimertinib) won expedited European approval for EGFR-positive advanced non-small cell lung cancer; it was approved by the U.S. FDA in November. Release

> China fined 5 domestic drugmakers almost 4 million yuan ($608,000) for price-fixing, saying they colluded to support the price of allopurinol, used to treat gout and kidney disease. Report

> The AIDS Healthcare Foundation sued Gilead Sciences ($GILD), accusing the company of holding back its next-gen TAF drug--now on its way to FDA approval--to allow a previous drug, tenofovir, to reap more sales. Report

And Finally... Teen girls with Type 1 diabetes are at higher risk of an eating disorder, with some skipping insulin doses to lose weight. Report

Suggested Articles

Alexion and Amgen reached a deal to put off a biosimilar challenger to Alexion's blockbuster rare disease med Soliris until March 2025.

AZ's tremelimumab has so far suffered a host of clinical failures. But new trial results show the company might be able to use the drug in a new way.

Roche may have just grabbed the first FDA nod for a checkpoint med in previously untreated liver cancer, but Merck is hoping it won’t be far behind.